3/5
11:44 am
psnl
Personalis (PSNL) had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
Low
Report
Personalis (PSNL) had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
2/27
08:02 am
psnl
Personalis (PSNL) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis (PSNL) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.
2/27
12:20 am
psnl
Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... [Yahoo! Finance]
Medium
Report
Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... [Yahoo! Finance]
2/26
11:47 pm
psnl
Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate [Seeking Alpha]
Medium
Report
Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate [Seeking Alpha]
2/26
11:39 pm
psnl
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
04:54 pm
psnl
Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M [Seeking Alpha]
High
Report
Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M [Seeking Alpha]
2/26
04:14 pm
psnl
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights [Yahoo! Finance]
High
Report
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights [Yahoo! Finance]
2/26
04:01 pm
psnl
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Low
Report
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
2/26
12:23 pm
psnl
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? [Yahoo! Finance]
Medium
Report
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? [Yahoo! Finance]
2/17
04:22 pm
psnl
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference [Yahoo! Finance]
2/17
04:01 pm
psnl
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Medium
Report
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
2/12
04:52 pm
psnl
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/12
04:01 pm
psnl
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
2/12
08:04 am
psnl
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $12.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its price target raised by analysts at BTIG Research from $12.00 to $13.00. They now have a "buy" rating on the stock.
2/10
06:00 am
psnl
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
High
Report
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
2/2
08:36 pm
psnl
Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]
2/2
06:24 am
psnl
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
Low
Report
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
2/2
06:00 am
psnl
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Low
Report
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
1/28
04:01 pm
psnl
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Low
Report
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
1/26
10:02 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/12
04:39 pm
psnl
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ [Yahoo! Finance]
Low
Report
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ [Yahoo! Finance]
1/12
04:00 pm
psnl
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
Low
Report
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
1/9
08:02 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $12.00 price target on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $12.00 price target on the stock.
1/8
08:00 am
psnl
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Medium
Report
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights